The Peripheral Neuropathic Pain market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Peripheral Neuropathic Pain pipeline products will significantly revolutionize the Peripheral Neuropathic Pain market dynamics.
DelveInsight’s “Peripheral Neuropathic Pain Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Peripheral Neuropathic Pain, historical and forecasted epidemiology as well as the Peripheral Neuropathic Pain market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Peripheral Neuropathic Pain market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
To Know in detail about the Peripheral Neuropathic Pain market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Peripheral Neuropathic Pain Market Forecast
Some of the key facts of the Peripheral Neuropathic Pain Market Report:
In 2023, the total peripheral neuropathic pain market size in the 7MM was approximately USD 12,000 million. This market is projected to grow significantly by 2034, driven by a substantial CAGR over the forecast period (2024–2034).
In November 2024, Lexicon Pharmaceuticals has concluded subject enrollment for the multicenter Phase IIb PROGRESS trial of LX9211, an adaptor-associated kinase 1 (AAK1) inhibitor aimed at treating diabetic peripheral neuropathic pain (DPNP). The trial recruited 494 participants, exceeding the initial target by nearly 20%, with top-line results expected in the first quarter of next year.
In November 2024, Averitas Pharma, the U.S. subsidiary of Grünenthal, has finalized patient enrollment for the Phase III AV001 clinical trial evaluating QUTENZA (capsaicin) 8% topical system for the treatment of post-surgical neuropathic pain (PSNP).
In July 2024, Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN), a clinical-stage company specializing in targeted immunotherapeutic drugs, has reported promising results from the Phase 1b segment of its Phase 1b/2a clinical trial evaluating SON-080 for chemotherapy-induced peripheral neuropathy (CIPN). The SB211 study, a double-blind, randomized, controlled trial conducted at two sites in Australia, assesses SON-080, a novel recombinant human Interleukin-6 (rhIL-6) formulation based on prior work with atexakin alfa. The Phase 1b portion aimed to confirm safety and tolerability before progressing to Phase 2. Following a March 2024 review, a data and safety monitoring board determined that symptoms in the first nine patients were tolerable, allowing the study to advance.
In May 2024, Lexicon Pharmaceuticals partnered with clinical trial solutions provider Medidata to support the Phase IIb PROGRESS study of LX9211, a non-opioid treatment candidate for diabetic peripheral neuropathic pain (DPNP).
In 2023, opioids dominated the U.S. Peripheral Neuropathic Pain market, generating approximately USD 2,400 million in revenue, while NSAIDs closely followed with around USD 2,300 million.
In 2023, NSAIDs generated the highest revenue for Peripheral Neuropathic Pain treatment among the EU4 and the UK, totaling approximately USD 600 million
In April 2024, Algiax Pharmaceuticals expanded its Phase IIa clinical trial of AP-325, a therapy aimed at chronic neuropathic pain, by adding 12 new sites across Belgium and France. This decision comes after encouraging interim analysis results during mid-enrollment and solid financial backing from the company’s investors. The AP-325.04 study, which is randomized and controlled, now includes a total of 25 active sites, incorporating research centers in the Czech Republic and Spain as well.
In 2023, the United States had the highest prevalence of peripheral neuropathic pain (PNP) among the 7MM, with approximately 35.2 million reported cases.
Among the 7MM, the highest number of severe cases were observed in post-operative and post-traumatic peripheral neuropathic pain (PNP), whereas moderate cases were more prevalent in postherpetic neuralgia (PHN).
In 2023, estimates suggest that the EU4 and the UK together recorded roughly 19.3 million cases, with Germany accounting for the largest portion, approximately 35% of the total cases.
In 2023, diabetic peripheral neuropathy (DPN) represented the largest proportion of cases in the US, making up about 50% of the total cases.
Key Peripheral Neuropathic Pain Companies: Grünenthal and Averitas Pharma, Scilex Pharmaceuticals, Apurano Pharmaceuticals, Lexicon Pharmaceuticals, Wex Pharmaceuticals, Helixmith, Lexicon Pharmaceuticals Inc., Bayer, AlzeCure Pharma, Grünenthal, Mallinckrodt Pharmaceuticals., Pfizer, Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., and others
Key Peripheral Neuropathic Pain Therapies: QUTENZA (capsaicin), ZTLIDO (lidocaine), SEMDEXA (SP-102), Adezunap (AP707), LX9211, Halneuron (Tetrodotoxin or TTX), ENGENSIS/VM202 (donaperminogene seltoplasmid), Halneuron, LX9211, BAY2395840, ACD440 gel, and others
The Peripheral Neuropathic Pain epidemiology based on gender analyzed that peripheral neuropathic pain affects females more as compared to males
Peripheral Neuropathic Pain Overview
Peripheral neuropathic pain refers to pain caused by damage or dysfunction of the peripheral nervous system. This condition arises when nerves outside of the brain and spinal cord (peripheral nerves) become injured, compressed, or otherwise impaired. It can result from various causes such as diabetes, infections, traumatic injuries, autoimmune diseases, or exposure to toxins.
Get a Free sample for the Peripheral Neuropathic Pain Market Report:
https://www.delveinsight.com/report-store/peripheral-neuropathic-pain-market
Peripheral Neuropathic Pain Market
The dynamics of the Peripheral Neuropathic Pain market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.
“The approval of novel therapies for the treatment of neuropathic pain has led to a major uptick in the diabetic peripheral neuropathic pain drugs market.”
Peripheral Neuropathic Pain Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Peripheral Neuropathic Pain Epidemiology Segmentation:
The Peripheral Neuropathic Pain market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Total Cases of Peripheral Neuropathic Pain in the 7MM
Type-specific Cases of Peripheral Neuropathic Pain in the 7MM
Treated Cases of Peripheral Neuropathic Pain in the 7MM
Download the report to understand which factors are driving Peripheral Neuropathic Pain epidemiology trends @ Peripheral Neuropathic Pain Epidemiological Insights
Peripheral Neuropathic Pain Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Peripheral Neuropathic Pain market or expected to get launched during the study period. The analysis covers Peripheral Neuropathic Pain market
uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Peripheral Neuropathic Pain Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Peripheral Neuropathic Pain Therapies and Key Companies
QUTENZA (capsaicin): Grünenthal and Averitas Pharma
ZTLIDO (lidocaine): Scilex Pharmaceuticals
SEMDEXA (SP-102): Scilex Holding Company
Adezunap (AP707): Apurano Pharmaceuticals
LX9211: Lexicon Pharmaceuticals
Halneuron (Tetrodotoxin or TTX): Wex Pharmaceuticals Inc.
ENGENSIS/VM202 (donaperminogene seltoplasmid): Helixmith
Halneuron: WEX Pharmaceuticals Inc.
LX9211: Lexicon Pharmaceuticals Inc.
BAY2395840: Bayer
ACD440 gel: AlzeCure Pharma
To know more about Peripheral Neuropathic Pain treatment, visit @ Peripheral Neuropathic Pain Medications
Peripheral Neuropathic Pain Market Strengths
With diabetic neuropathy being the most common chronic complication of diabetes, the prevalent population of diabetic neuropathy is already large.
With the growing prevalence of cancer and increased chemotherapy usage, more attention is being drawn toward CIPN.
With a significantly larger patient pool, recent developmental activities around LSR have highlighted the market potential of pain management in LSR.
Peripheral Neuropathic Pain Market Opportunities
Since the current treatment landscape lacks a disease-modifying treatment option and is solely dependent on symptomatic relief, emerging disease-modifying therapies cannot only expect to have a high uptake but also charge a significant premium price.
The targeting of novel targets like adapter associated kinase 1 (AAK1) and Nav1.8 voltage-gated sodium channel has the potential of placing themselves as a replacement to opioid treatment, providing pain relief without the limitations of opioids, including their addictive potential.
Scope of the Peripheral Neuropathic Pain Market Report
Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Peripheral Neuropathic Pain Therapeutic Assessment: Peripheral Neuropathic Pain current marketed and Peripheral Neuropathic Pain emerging therapies
Peripheral Neuropathic Pain Market Dynamics: Peripheral Neuropathic Pain market drivers and Peripheral Neuropathic Pain market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Peripheral Neuropathic Pain Unmet Needs, KOL’s views, Analyst’s views, Peripheral Neuropathic Pain Market Access and Reimbursement
Discover more about therapies set to grab major Peripheral Neuropathic Pain market share @ Peripheral Neuropathic Pain Treatment Landscape
Table of Contents
1. Peripheral Neuropathic Pain Market Report Introduction
2. Executive Summary for Peripheral Neuropathic Pain
3. SWOT analysis of Peripheral Neuropathic Pain
4. Peripheral Neuropathic Pain Patient Share (%) Overview at a Glance
5. Peripheral Neuropathic Pain Market Overview at a Glance
6. Peripheral Neuropathic Pain Disease Background and Overview
7. Peripheral Neuropathic Pain Epidemiology and Patient Population
8. Country-Specific Patient Population of Peripheral Neuropathic Pain
9. Peripheral Neuropathic Pain Current Treatment and Medical Practices
10. Peripheral Neuropathic Pain Unmet Needs
11. Peripheral Neuropathic Pain Emerging Therapies
12. Peripheral Neuropathic Pain Market Outlook
13. Country-Wise Peripheral Neuropathic Pain Market Analysis (2020–2034)
14. Peripheral Neuropathic Pain Market Access and Reimbursement of Therapies
15. Peripheral Neuropathic Pain Market Drivers
16. Peripheral Neuropathic Pain Market Barriers
17. Peripheral Neuropathic Pain Appendix
18. Peripheral Neuropathic Pain Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/
